Who Paid My Doc
Beleodaq
Drug Oncology
NDC 72893-002-01
General payments
$1,209,760
Research payments
$1,233,475
Through program year 2025, $1,209,760 in general payments and $1,233,475 in research payments were reported against Beleodaq (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $233,929 | 1,350 |
| 2025 | Research | $734,102 | 63 |
| 2024 | General | $266,321 | 1,455 |
| 2024 | Research | $83,159 | 13 |
| 2023 | General | $399,324 | 1,212 |
| 2023 | Research | $238,022 | 28 |
| 2022 | General | $214,081 | 1,777 |
| 2022 | Research | $67,359 | 3 |
| 2021 | General | $29,678 | 1,195 |
| 2021 | Research | $61,000 | 1 |
| 2020 | General | $31,481 | 337 |
| 2020 | Research | $13,807 | 2 |
| 2019 | General | $34,946 | 187 |
| 2019 | Research | $36,026 | 2 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 47 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 46 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
7,513 general · 112 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.